OpenAI Acquires Drug-Development Platform Orchestra Bio to Accelerate Medicine Discovery

OpenAI announced on October 21, 2026 the acquisition of Orchestra Bio, a four-year-old startup that raised $20 million when it exited stealth in 2025. Orchestra Bio built a platform that lets biopharma teams deploy AI agents to monitor scientific studies, track drug development timelines and flag potential delays before they cause problems — essentially automating the coordination work that ties up researchers throughout the drug pipeline. OpenAI is bringing Orchestra's team, led by founder and CEO Ashoka Rajendra, together with Rosalind, the company's existing life-sciences AI suite built around GPT-Rosalind, a reasoning model launched in April 2026 targeting drug discovery, genomics analysis and protein reasoning. Financial terms of the acquisition were not disclosed. OpenAI said the combined platform aims to help scientists make more discoveries and move promising medicines to patients sooner, with the broader goal of compressing the typical 10–15-year drug development timeline significantly. The deal intensifies competition with Anthropic, which acquired Coefficient Bio for approximately $400 million in April 2026. The story was first reported by Axios as an exclusive.